secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001549595-25-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%
--------------------------------------------------------------------------------

- Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.
- Cash and marketable securities $609.6M as of Nov 30, 2024, up from $295.3M a year earlier.
- NX-5948 achieved 75.5% objective response rate in r/r CLL/SLL; received FDA Fast Track and EMA PRIME designations.
- Appointed John Northcott as Chief Commercial Officer in January 2025.
- Plans to commence registration trials for NX-5948 in CLL and explore autoimmune indications in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/0001549595-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/nrix-20250128.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer